Lumos Pharma, Inc. LUMO
4.34 0.00 (+0.00%)
At closeDec 11, 2024, 4:00 PM EST
4.33 Day range 4.34
52-week range unavailable
- Market cap
- 37.54M
- Revenue (ttm)
- 2.21M
- Shares out
- 8.65M
- Forward P/E
- -2.01
- Volume
- 390.87K
- Open
- 4.33
- Previous close
- 4.34
- Day's range
- 4.33 – 4.34
- Beta
- 0.33
- Analysts
- Buy
- Price target
- 4.25 (-2.1%)
- Earnings date
- Nov 7, 2024
No chart data for this range yet.
Key statistics
- Enterprise value
- 24.19M
- PEG ratio
- 0.00
- Price / sales
- 17.02
- Price / book
- 7.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 10271.40%
- Free cash flow
- -19.43M
- Total cash
- 13.52M
- Total debt
- 172.00K
- Return on equity
- -172.83%
- Short % of float
- 0.87%
- 50-day average
- 4.23
- 200-day average
- 3.10
Analyst view
Consensus: buy
Buy
Price target (mean) 4.25
Ratings (0m) 2 1 buy · 1 hold · 0 sell
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 7, 2024
Expected Nov 7, 2024. Consensus EPS estimate -0.56.
Financials — quick view
LUMO Revenue — quarterly 726.00K
LUMO Net income — quarterly -7.47M
LUMO EPS — quarterly -0.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.56 | — | — | — |
| Aug 1, 2024 | Jun 1, 2024 | -1.26 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -1.21 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -1.18 | — | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -1.10 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -1.06 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Oct 24, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 23, 2024 | Jones Trading | down | Buy | Hold |
| Sep 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 24, 2024 | EF Hutton | init | — | Buy |
| Aug 2, 2024 | Oppenheimer | main | Outperform | Outperform |
About Lumos Pharma, Inc.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc. was taken private.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lumos-pharma.com
News
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma 
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO 
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc. 
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders 
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders 
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024 
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference 
Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript 
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update 
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
Your note
Sign in to keep a note on LUMO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HAWKINS RICHARD JAMES | Chief Executive Officer | Stock Award(Grant) | Mar 31, 2024 | 757,562 |
| KARPF DAVID B. M.D. | Officer | Stock Award(Grant) | Jan 31, 2023 | 8,294 |
| LAWLEY LORI D | Chief Financial Officer | Stock Award(Grant) | Mar 31, 2024 | 12,513 |
| MCKEW JOHN C | Officer | Sale | Aug 5, 2024 | 12,653 |
| PITUKCHEEWANONT PISIT DUKE M.D. | Officer | Stock Award(Grant) | Mar 31, 2024 | 16,930 |
| POWERS BRADLEY J | Officer | Stock Award(Grant) | Mar 31, 2024 | 6,334 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Private Advisor Group, LLC | 8.61% | 744,513 | 3.23M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 4.19% | 362,198 | 1.57M | Sep 29, 2024 |
| Vanguard Group Inc | 2.82% | 244,082 | 1.06M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.47% | 213,814 | 927.95K | Sep 29, 2024 |
| Jefferies Financial Group Inc. | 1.40% | 120,651 | 523.63K | Sep 29, 2024 |
| Greenwich Wealth Management Llc | 0.88% | 76,341 | 331.32K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.17% | 187,322 | 812.98K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.59% | 50,828 | 220.59K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 29,993 | 130.17K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 18,744 | 81.35K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 9,129 | 39.62K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.10% | 8,658 | 37.58K | Oct 30, 2024 |